The central nervous system-focused drug developer has raised approximately $124m so far from investors including 3M.
Impel NeuroPharma, a US-based central nervous system drug developer backed by manufacturing group 3M, has filed to raise $75m in an initial public offering on the Nasdaq Global Market.
Founded in 2008, Impel is developing therapies for patients with central nervous system disorders. It has also developed a medical device that delivers medicine to the upper nasal cavity.
The IPO proceeds will be used to commercialise and secure regulatory approval for the company’s lead drug candidate Trudhesa, a prospective…
